Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Urged To Change OTC Monograph System, But Not In Midstream

This article was originally published in The Tan Sheet

Executive Summary

“Moving away from the monograph system when we are so close to the end” would “risk setting back the OTC drug review many years or even decades,” CHPA head Scott Melville says at an FDA public hearing. Other stakeholder s explain how the monograph system has failed industry and consumers.

You may also be interested in...



FDA Lifts Curtain On Homeopathics Regulatory Evaluation With Public Hearing

FDA’s public hearing announcement comes a week after it alerted consumers to the prevalence of homeopathics with violative indications for treating asthma and could signal the start of the separate review of homeopathic regulations the agency said it would undertake when the OTC drug review began in 1972.

FDA Lifts Curtain On Homeopathics Regulatory Evaluation With Public Hearing

FDA’s public hearing announcement comes a week after it alerted consumers to the prevalence of homeopathics with violative indications for treating asthma and could signal the start of the separate review of homeopathic regulations the agency said it would undertake when the OTC drug review began in 1972.

Sunscreen Ingredient TEA Decisions Highlight Challenges Of NDA Scale

The TEA option has not provided a more efficient and economical method for drug industry stakeholders to convince FDA to expand OTC monographs with ingredients that have demonstrated safety records in foreign markets, but rather a system that rivals the rigors of the new drug application process. Former FDA attorneys offer perspective.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS106828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel